CR11221A - Estirpes celulares aviares inmortalizadas - Google Patents

Estirpes celulares aviares inmortalizadas

Info

Publication number
CR11221A
CR11221A CR11221A CR11221A CR11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A
Authority
CR
Costa Rica
Prior art keywords
immortalized
stones
cells
aircraft cellular
aircraft
Prior art date
Application number
CR11221A
Other languages
English (en)
Inventor
Philipppe Erbs
Marina Kapfer
Nathalie Silvestre
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39767102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of CR11221A publication Critical patent/CR11221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a celulas aviares inmortalizadas, y al uso de estas celulas para la produccion de virus. Las celulas segun la invencion son particularmente utiles para la produccion de vectores viricos recombinantes que se pueden usar para la preparacion de composiciones terapeuticas y/o profilacticas para el tratamiento de animales, y mas particularmente seres humanos.
CR11221A 2007-07-03 2010-01-15 Estirpes celulares aviares inmortalizadas CR11221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07360030 2007-07-03

Publications (1)

Publication Number Publication Date
CR11221A true CR11221A (es) 2010-03-22

Family

ID=39767102

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11221A CR11221A (es) 2007-07-03 2010-01-15 Estirpes celulares aviares inmortalizadas

Country Status (15)

Country Link
US (2) US8361788B2 (es)
EP (1) EP2176398B1 (es)
JP (1) JP5421250B2 (es)
KR (1) KR101528379B1 (es)
CN (1) CN101688182A (es)
AU (1) AU2008270317B2 (es)
BR (1) BRPI0811787B1 (es)
CA (1) CA2691868C (es)
CR (1) CR11221A (es)
ES (1) ES2618490T3 (es)
IL (1) IL203029A (es)
RU (1) RU2475536C2 (es)
TW (1) TWI614342B (es)
WO (1) WO2009004016A1 (es)
ZA (1) ZA201000251B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
NZ596595A (en) * 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
FR2956409A1 (fr) 2010-02-15 2011-08-19 Univ Claude Bernard Lyon Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
JP6546659B2 (ja) * 2014-12-04 2019-07-17 インターベット インターナショナル ベー． フェー． 不死化ニワトリ胚線維芽細胞
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
EP3884039A1 (en) 2018-11-23 2021-09-29 Valneva SE Food products comprising avian stem cells
FR3089789B1 (fr) 2018-12-14 2022-05-27 Univ Claude Bernard Lyon Production de vaccins viraux sur une lignee cellulaire aviaire
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749021B1 (fr) 1996-05-23 2001-10-26 Agronomique Inst Nat Rech Lignees de cellules aviaires immortalisees
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2836924B1 (fr) * 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN1826410B (zh) 2003-07-21 2011-10-26 特兰斯吉恩股份有限公司 具有改良的胞嘧啶脱氨酶活性的多肽
PT1646715E (pt) 2003-07-22 2010-08-09 Vivalis Produção de poxvírus com linhagem das células aviarias aderentes ou não aderentes
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production

Also Published As

Publication number Publication date
US8361788B2 (en) 2013-01-29
EP2176398A1 (en) 2010-04-21
US8809056B2 (en) 2014-08-19
EP2176398B1 (en) 2016-12-28
ZA201000251B (en) 2010-09-29
RU2010102668A (ru) 2011-08-10
KR20100035650A (ko) 2010-04-05
TW200911994A (en) 2009-03-16
CA2691868C (en) 2016-12-20
KR101528379B1 (ko) 2015-06-16
RU2475536C2 (ru) 2013-02-20
CA2691868A1 (en) 2009-01-08
IL203029A (en) 2013-07-31
US20130244246A1 (en) 2013-09-19
BRPI0811787B1 (pt) 2018-10-09
AU2008270317B2 (en) 2013-12-05
ES2618490T3 (es) 2017-06-21
US20100197010A1 (en) 2010-08-05
JP2010531654A (ja) 2010-09-30
AU2008270317A1 (en) 2009-01-08
JP5421250B2 (ja) 2014-02-19
WO2009004016A1 (en) 2009-01-08
TWI614342B (zh) 2018-02-11
CN101688182A (zh) 2010-03-31
BRPI0811787A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
UY36966A (es) Derivados de heterociclos bicíclicos fusionados como plaguicidas
UY31484A1 (es) Piperidinas heteroaril-sustituidas
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
HN2008000087A (es) Inhibidores de la proteasa ns3 del vhc
MX2019002606A (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
CR9131A (es) Oligonucleotidos inmunoestimuladores de clase c semiblandos
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
ECSP11011249A (es) Derivados de fosforamidato de compuestos nucleósidos de guanosina para el tratamiento de infecciones virales
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CY1117778T1 (el) Βελτιωμενη ανασυνδυασμενη ανθρωπινη ωοθυλακιοτροπο ορμονη
UY32457A (es) Vacuna del virus del dengue inactivado
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)